Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and...
share announcement

New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies (2nd Edition)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 15 October 2025 | Viewed by 9402

Special Issue Editors

Dr. Ilaria Stefania Pagani

E-Mail Website
Guest Editor
Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute, Adelaide 5000, Australia
Interests: metabolism; cancer relapse; precision medicine; microbiome; immunology; drug discovery; leukaemia
Special Issues, Collections and Topics in MDPI journals
Dr. Teresa Sadras

E-Mail Website
Guest Editor
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
Interests: B cell development; acute lymphoblastic leukemia; cytokine receptors; cell signaling; cancer genomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are excited to invite you to contribute to this Special Issue, which is the second edition of "New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies" (https://www.mdpi.com/journal/cancers/special_issues/haematological_malignancies).

It is our pleasure to announce a call for submissions to this Special Issue of Cancers, titled "New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies".

Blood cancer is one is the major causes of cancer death worldwide. Patients have increased chances of surviving if the disease is diagnosed earlier, and people have access to better personalised therapies. Additionally, toxicities and long-term adverse effects, including organ damage, are often associated with current blood cancer therapies and impair life quality. In the last decade, novel genetic, epigenetic, metabolic, and immunological vulnerabilities have been identified and, in some cases, have led to the development of new targeted therapies. However, despite rapid initial responses, disease often recurs with an often-fatal outcome. We welcome original research articles and reviews that cover any relevant topics in this area. Possible topics include, but are not limited to, the following:

  • Role of the immune system in blood cancer progression and relapse and advances in immunotherapies.
  • Mechanisms of resistance and targeted therapies.
  • Genomic and epigenetic mechanisms influencing clinical outcome, including mutations, gene fusions, copy number variations, and other chromosomal rearrangements.
  • Exploiting metabolic vulnerabilities for personalised therapies, including mutations in key metabolic enzymes.
  • Side effects and toxicities of the current blood cancer therapies and strategies for reducing them.
  • Omics approaches, including single-cell technologies, for identifying new biomarkers.
  • RAS pathway mutations in blood cancer and new targeted therapies.
  • The tumour microenvironment, cell dormancy, and relapse.

We look forward to receiving your contributions.

Dr. Ilaria Stefania Pagani
Dr. Teresa Sadras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood cancer
  • cancer relapse
  • resistance
  • targeted therapies
  • immune therapies
  • metabolism
  • cancer mutations

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

20 pages, 1747 KiB  
Article
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk
by Damian Mikulski, Marcin Kamil Kędzior, Grzegorz Mirocha, Katarzyna Jerzmanowska-Piechota, Żaneta Witas, Łukasz Woźniak, Magdalena Pawlak, Kacper Kościelny, Michał Kośny, Paweł Robak, Aleksandra Gołos, Tadeusz Robak, Wojciech Fendler and Joanna Góra-Tybor
Cancers 2024, 16(21), 3709; https://doi.org/10.3390/cancers16213709 - 3 Nov 2024
Cited by 1 | Viewed by 3125
Abstract
Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND) and relapsed/refractory (RR) patients. However, previous reports indicated an increased risk of infectious [...] Read more.
Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND) and relapsed/refractory (RR) patients. However, previous reports indicated an increased risk of infectious complications (ICs) during Dara-based treatment. In this study, we aimed to determine the profile of ICs in MM patients treated with Dara-based regimens and establish predictors of their occurrence. Methods: This retrospective, real-life study included MM patients treated with Dara-based regimens between July 2019 and March 2024 at our institution. Infectious events were evaluated using the Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: The study group consisted of a total of 139 patients, including 49 NDMM and 90 RRMM. In the RR setting, the majority (60.0%) of patients received the Dara, bortezomib, and dexamethasone (DVd) regimen, whereas ND patients were predominantly (98%) treated with the Dara, bortezomib, thalidomide, and dexamethasone (DVTd) regimen. Overall, 55 patients (39.6%) experienced ICs. The most common IC was pneumonia (37.5%), followed by upper respiratory tract infections (26.8%). Finally, twenty-five patients had severe ICs (grade ≥ 3) and required hospitalization, and eight patients died due to ICs. In the final multivariable model adjusted for setting (ND/RR) and age, hemoglobin level (OR 0.77, 95% CI: 0.61–0.96, p = 0.0037), and Eastern Cooperative Oncology Group (ECOG) >1 (OR 4.46, 95% CI: 1.63–12.26, p = 0.0037) were significant factors influencing severe IC occurrence. Additionally, we developed predictive models using the J48 decision tree, gradient boosting, and random forest algorithms. After conducting 10-fold cross-validation, these models demonstrated strong performance in predicting the occurrence of pneumonia during treatment with daratumumab-based regimens. Conclusions: Simple clinical and laboratory assessments, including hemoglobin level and ECOG scale, can be valuable in identifying patients vulnerable to infections during Dara-based regimens, facilitating personalized prophylactic strategies. Full article
(This article belongs to the Special Issue New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies (2nd Edition))
►▼ Show Figures

Figure 1

13 pages, 1513 KiB  
Article
The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population
by Silvana A. M. Urru, Flavia Mayer, Stefania Spila Alegiani, Francesca Paoloni, Anna Guella, Roberta Murru, Giampaolo Bucaneve, Giulio Formoso, Vito Racanelli, Isacco Ferrarini, Claudio Fozza, Giuseppe Longo, Felice Musicco and Annalisa Campomori
Cancers 2024, 16(19), 3419; https://doi.org/10.3390/cancers16193419 - 8 Oct 2024
Viewed by 1631
Abstract
The clinical safety and efficacy of rituximab biosimilars compared to the reference rituximab (Mabthera) have been well established in randomized trials. However, concerns persist regarding the safety of changing from the reference product to biosimilars, and particularly between different biosimilars. This prospective multicenter [...] Read more.
The clinical safety and efficacy of rituximab biosimilars compared to the reference rituximab (Mabthera) have been well established in randomized trials. However, concerns persist regarding the safety of changing from the reference product to biosimilars, and particularly between different biosimilars. This prospective multicenter observational study was conducted in 13 oncohematology units of eight Italian regions. The study included 800 patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) who received rituximab between March 2018 and June 2022. To minimize survivorship bias, only newly diagnosed patients (i.e., those without prior rituximab treatment) were included in the analysis of adverse drug reactions (ADRs). Thus, this study focused on 505 incident cases (79.8% of the initial cohort) from 13 centers. A total of 3681 rituximab infusions were administered, and 16.8% of the patients experienced at least one ADR. These were observed most frequently during the first infusion (44 patients, 52%) and the second infusion (17 patients, 20%). The most frequent reactions were general disorders and administration site conditions (n. 50, 8% serious). These findings support the clinical safety of rituximab biosimilars and suggest that switching between biosimilars does not increase the risk of adverse events. This evidence may alleviate concerns about biosimilar use, potentially leading to broader acceptance and reduced healthcare costs. Full article
(This article belongs to the Special Issue New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies (2nd Edition))
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 438 KiB  
Review
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
by Francesco D’Alò, Silvia Bellesi, Elena Maiolo, Eleonora Alma, Flaminia Bellisario, Rosalia Malafronte, Marcello Viscovo, Fabrizia Campana and Stefan Hohaus
Cancers 2024, 16(12), 2243; https://doi.org/10.3390/cancers16122243 - 17 Jun 2024
Cited by 6 | Viewed by 4062
Abstract
Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients’ chance of being cured and clinicians’ therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with [...] Read more.
Since the introduction of rituximab in the late 1990s, significant progress has been made in advancing targeted therapies for B cell lymphomas, improving patients’ chance of being cured and clinicians’ therapeutic armamentarium. A better understanding of disease biology and pathogenic pathways, coupled with refinements in immunophenotypic and molecular diagnostics, have been instrumental in these achievements. While traditional chemotherapy remains fundamental in most cases, concerns surrounding chemorefractoriness and cumulative toxicities, particularly the depletion of the hemopoietic reserve, underscore the imperative for personalized treatment approaches. Integrating targeted agents, notably monoclonal antibodies, alongside chemotherapy has yielded heightened response rates and prolonged survival. A notable paradigm shift is underway with innovative-targeted therapies replacing cytotoxic drugs, challenging conventional salvage strategies like stem cell transplantation. This review examines the landscape of emerging targets for lymphoma cells and explores innovative therapies for diffuse large B cell lymphoma (DLBCL). From Chimeric Antigen Receptor-T cells to more potent monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, checkpoint inhibitors, and small molecules targeting intracellular pathways, each modality offers promising avenues for therapeutic advancement. This review aims to furnish insights into their potential implications for the future of DLBCL treatment strategies. Full article
(This article belongs to the Special Issue New Precision Medicine Approaches in Haematological Malignancies: Novel Targets and Advanced Therapies (2nd Edition))
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop